PDCD1 and melanoma: Since then, additional therapies have been approved for the treatment of advanced stage melanoma, both targeted therapies [4–8] and immunotherapies, including the newly FDA approved antagonist programmed cell death protein 1 (PD-1) antibodies, pembrolizumab and nivolumab [9–12].